Our story

Founded in 2007, Lucid Group has grown from a small UK-based medical education agency to a global healthcare consultancy and employing over 400 people with several offices in the UK and US.

We partner with the pharma and biotech industry to deliver pioneering solutions that change behaviour, improve clinical practice and advance health outcomes.

arrow pointing down

Our purpose is clear.
We transform lives

By connecting our best-in-class capabilities and applying them at the right time we can better understand and fix healthcare problems with outcomes-led solutions, expertly executed to deliver life-transforming value for everyone.

Recognised as industry leaders

We have loads to be proud of and continue to receive the most coveted accolades for our work, winning multiple industry awards for our clients:

17

COMMUNIQUÉ
AWARDS

11

PHARMACEUTICAL MARKETING
EXCELLENCE AWARDS

9

AGENCY OF THE
YEAR AWARDS

Since 2007

Some of our proudest transformations...

Delivering outcomes-led solutions for our clients and
transforming the lives of those they touch.

...

INFLAMMATORY BOWEL DISEASE

We achieved a paradigm shift in the disease management of inflammatory bowel disease (IBD)

By partnering with experts and identifying shared goals between the pharmaceutical industry and healthcare professional (HCP) we helped our clients pioneer a new approach to optimising treatment for IBD patients. This changed clinical practice and advanced health outcomes for patients globally.

...

MULTIPLE SCLEROSIS

We optimised services and care for people with multiple sclerosis (MS) across the UK, in line with NICE Quality Standards

The application of our behaviour change methodology, Advance Outcomes™, has supported the optimisation of MS services across the UK, creating measurable improvements in clinical and NHS cost outcomes. By engaging more than half of UK MS specialist nurses, we supported service developments such as new pathways for the full spectrum of MS, including treatment initiation, relapse care and safety monitoring. Services meeting the NICE Quality Standards for patient annual review increased by 50% between 2017 and 2018, which means more people with MS are receiving personalised, proactive, preventative care.

...

RHEUMATOID ARTHRITIS

We optimised disease control for patients with rheumatoid arthritis (RA)

Through peer-to-peer facilitation and use of behaviour-change principles, we created an international educational programme for our clients that addressed the missing links in the management of RA. This drove a clinical practice change to achieve better RA disease management, with support and follow-up from their Medical Science Liaison team to embed lasting change.

...

ONCOLOGY

We secured access to life-changing oncology treatment

By applying our behaviour change model, Advance Outcomes™, to a multichannel ecosystem to drive advocacy and influence change, we amplified the voice of early adopters and clinical experts who described the medicine as a step change in the treatment of cutaneous squamous-cell carcinoma, driving a paradigm shift in disease management.

...

PSORIASIS

We changed disease classification at the highest level

In partnership with the International Federation of Psoriasis Associations (IFPA), we amplified the patient voice to drive a policy change at the level of the World Health Organization (WHO) and United Nations (UN) that changed the disease classification of psoriasis to a severe non-communicable disease. This improved recognition of the impact of psoriasis globally.

...

STROKE PREVENTION

We inspired HCPs with a future-focused educational programme to take action to improve services in their locality for patients with atrial fibrillation

The programme focussed on driving enhanced performance in three key areas aligned with National Health Service (NHS) priorities: DETECT (find and diagnose more individuals with atrial fibrillation); PROTECT (ensure diagnosed patients are offered anticoagulation); and PERFECT (deliver best clinical practice in anticoagulation care). This programme has empowered HCPs in the UK to find and diagnose people with atrial fibrillation using the latest innovations in detection approaches and technology, with the aim of preventing strokes, saving lives and reducing the impact on healthcare systems.

...

HIDRADENITIS SUPPURATIVA

We revolutionised access to specialist-level care for the hidradenitis suppurativa (HS) community on a global scale

Through the facilitation of expert consensus building, we enabled experts to navigate evidence gaps and create practical recommendations we transformed access to care by raising awareness of HS with over 4,500 dermatologists worldwide. This led to the establishment of 135 new HS specialists and 45 new HS specialist clinics – advancing the quality of care for over 1,800 patients/month.

...

INFLUENZA

We pioneered an engaging research-based public health campaign

We partnered our behaviour change approach with creative and storytelling techniques to create a compelling and impactful public health campaign that drove nearly half (43.37%) of the surveyed unvaccinated populated to get their flu vaccine.

Diversity
& Inclusivity

At Lucid we know that diversity drives innovation. We firmly believe that the more inclusive we are, the better our team and work will be.

tell me more
Career Progression & Personal Growth

Growth is at the heart of #LucidLife. To look after our talented and diverse colleagues we know that we need to provide them with opportunities to grow as we grow.

tell me more
Lucid Spirit

Our ultimate purpose is to transform lives. Always. That extends far beyond the brilliant work we deliver for clients. Lucid Spirit is all about making a difference in our wider communities. Fundraising, volunteering, donating.

tell me more
We transform lives. Always. Get in touch to find out more.
get in touch